Parkinson's Treatment Advancements: Clinical Trials Begin for Potential New Therapy

1. James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
2. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Gain Therapeutics Inc. (GANX:NASDAQ) has announced the initiation of its Phase 1b clinical trial for GT-02287, a lead candidate targeting Parkinson's disease (PD), following regulatory approval in Australia. This open-label trial will evaluate the safety and tolerability of GT-02287 over a three-month dosing period in patients diagnosed with either idiopathic or GBA1-PD. Enrollment is expected to be completed by Spring 2025, with results anticipated mid-year.

The trial builds on the success of the earlier Phase 1 study in healthy volunteers, where GT-02287 demonstrated a favorable safety profile and significant engagement with the glucocerebrosidase (GCase) enzyme, a critical marker in Parkinson's disease. According to Gain Therapeutics in the news release, the drug showed a statistically significant increase in GCase activity, exceeding 50% improvement. Dr. Jonas Hannestad, Chief Medical Officer of Gain, highlighted the enthusiasm from both investigators and potential participants in Australia, a region historically underrepresented in PD clinical trials.

Preclinical data further support GT-02287's potential as a disease-modifying therapy. The compound, a brain-penetrant allosteric modulator, has demonstrated efficacy in restoring GCase enzymatic function, reducing neuroinflammation, and improving motor and cognitive performance in PD models. Financially supported by organizations such as the Michael J. Fox Foundation and The Silverstein Foundation, GT-02287 is positioned as a promising candidate in the estimated US$4 billion market for Parkinson's therapies.

A Look Into The Biotechnology and Pharmaceutical Industry

According to Coolest Gadgets on November 6, the global biotechnology market was valued at approximately US$1.024 trillion in 2022, with projections estimating growth to US$3.673 trillion by 2032. This growth is attributed to advancements in areas like proteomics, synthetic biology, and gene editing technologies such as CRISPR-Cas9, which have enabled the creation of novel therapeutics and solutions. The healthcare segment accounted for 35.8% of biotechnology revenue in 2022, driven by rising demand for personalized medicine, a trend that has spurred growth in biopharmaceuticals, which comprise nearly 40% of global drug sales. Additionally, biopharmaceuticals have been a focal point due to their large molecular structures and role in addressing complex diseases. North America has remained a leader in the sector, holding a 39.4% revenue share in 2022, supported by advanced research infrastructure and a skilled workforce.

Roth reiterated a Buy rating with a 12-month price target of US$7, citing the drug's innovative mechanism of action and its potential to transform Parkinson's treatment pathways.

Investor's Business Daily reported on December 20 that despite some challenges within the biotech sub-industry, the sector demonstrated resilience. The 735-company Medical-Biomed/Biotech group saw a 4% decline following political uncertainties tied to the incoming U.S. administration.

However, the sector maintained a Relative Strength Rating of 67, ranking in the top third of tracked industry groups. This highlights the industry's ability to adapt to market changes and political dynamics while continuing its focus on innovation.

India's pharmaceutical sector gained momentum, with the government aiming to establish the country as the "pharmacy of the world," according to The Economic Times on December 30. Arunish Chawla, Secretary of the Department of Pharmaceuticals, highlighted the success of the production-linked incentives (PLI) scheme, stating, "50 greenfield plants in the pharma and medical-tech sectors have started operating, and 50 more are in the pipeline." This initiative has fostered innovation and increased exports, with promising developments in blockbuster molecules for conditions such as cancer and diabetes. The pharmaceutical industry has also benefitted from a strong performance in the stock market, with pharma and healthcare mutual funds offering an average return of 38.05% in 2024. The Nifty Pharma Index posted a 23.59% year-over-year profit growth, reflecting the industry's strong momentum despite broader market volatility.

Factors Driving Growth For Gain Therapeutics

Gain Therapeutics' investor presentation identifies GT-02287 as a key driver of the company's pipeline, with multiple anticipated milestones in 2025. Interim results from the Phase 1b trial, expected in mid-2025, will provide critical safety and biomarker data, forming the foundation for Phase 2 preparation in the U.S. and EU by the second half of 2025. The company believes that the drug's novel mechanism of action, targeting GCase dysfunction, positions it uniquely in the PD treatment landscape, where existing therapies primarily manage symptoms without addressing underlying disease progression.

The company leverages its proprietary Magellan AI platform to identify and develop assets, further strengthening its competitive positioning. Gain states that it also benefits from a strong intellectual property portfolio, with patents extending through 2038. Additionally, the company's experienced leadership and grant support enhance its ability to advance GT-02287 and explore broader applications in neurodegenerative and lysosomal storage disorders. 

Buy-Rated

Third-party assessments of Gain Therapeutics highlighted significant advancements and positive outlooks for its flagship program, GT-02287, particularly in Parkinson's disease treatment.

According to H.C. Wainwright & Co., the company presented favorable preclinical proof-of-concept data for GT-02287, showcasing its safety and tolerability in early trials. They noted a 53% increase in GCase activity, as well as reductions in neurodegenerative markers such as α-synuclein aggregation and mitochondrial reactive oxygen species, which indicate the drug's potential for disease modification. The firm reiterated its Buy rating and established a 12-month price target of US$8, supported by Gain's robust preclinical results and the ongoing advancement of GT-02287 into Phase 1b trials.

In a report from Roth Capital Partners, the analysis emphasized the receipt of Australian regulatory approval for GT-02287's Phase 1b trials in Parkinson's patients, a milestone demonstrating the company's regulatory and clinical progress. The report highlighted the potential for GT-02287 to provide neuroprotection and improve biomarkers such as GCase activity, glucosylceramides, and ceramide levels. Roth reiterated a Buy rating with a 12-month price target of US$7, citing the drug's innovative mechanism of action and its potential to transform Parkinson's treatment pathways.

Ownership and Share Structure

About 5% of the company is owned by insiders and management, according to Refinitiv.

About 6% is institutional. The rest is retail.

Top shareholders include Founder and Executive Chairman Khalid Islam with 3.59%, Greenlight Capital Inc. with 2.18%, Gotham Asset Management LLC with 1.29%, Independent Board Member Eric Richman with 1.17%, and Geode Capital Management LLC with 1.05%.

It has 25.96 million shares outstanding, 24.66 million free floating shares. Its market cap is US$46.47 million and trades in a 52-week range of US$0.89 and US$5.33.